Cure Leukaemia Announces Vital Funding for Global TP53 Initiative to Combat High-Risk Myeloid Malignancies
Cure Leukaemia is proud to announce its official funding and support for the TP53 Initiative, a groundbreaking clinical collaboration, registry database and biobanking initiative designed to transform outcomes for patients with TP53-mutated myeloid malignancies who are eligible for stem cell transplantation. The Cure Leukaemia funding will directly contribute to the formation of the TP53 Registry.
Led by Chief Investigator Dr. Mili Shah at King’s College Hospital NHS Foundation Trust, the initiative targets a patient group, those with TP53-mutated Acute Myeloid Leukaemia (AML) or Myelodysplastic Syndrome (MDS), who have seen very little progress in drug therapy for over three decades.
The TP53 Registry is a prospective clinical database that will systematically collect data not just on patients recruited to the initiative-e but all patients with TP53 mutations. With the support of the IMPACT and the AML Research Network, the registry will be delivered across centres within the UK- with a future view to expanding internationally, providing a robust infrastructure for clinical insight.
“The TP53 Initiative is a vital step forward for a patient group that has historically had very poor outcomes,” said Dr. Mili Shah. “It has been a crucial collaborative effort from clinicians across the UK and the world to make a difference in this area of unmet need. The TP53 Registry will provide live feedback of vital data for these patients, allowing scope for future clinical studies and research, and important changes in practice by unified evidence based medicine”. The support from Cure Leukaemia has been instrumental in making this registry a reality, providing the foundation we need to improve patient care.”
The initiative is part of an international effort overseen by TP53-I-CONNECT, a collaborative network dedicated to improving outcomes through shared clinical and translational research.
Cure Leukaemia’s funding of the setup and establishment of this registry underscores the charity’s commitment to innovative, data-led initiatives that bring clinical teams closer to a cure.
“This partnership aligns perfectly with Cure Leukaemia’s core mission,” said James McLaughlin, CEO of Cure Leukaemia. “We are committed to helping clinical teams advance data, innovation, and treatments for blood cancer patients. By supporting the TP53 Registry, we are ensuring that researchers have the high-quality data necessary to break the decades-long stalemate in treating these high-risk malignancies.”